SCHEMBL25933244

SCHEMBL25933244

CCCN(C)c1nc(C)cs1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.38
NOS1 P29475 1/20 0.38
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
SLC12A5 Q9H2X9 2/20 0.33
CYP2D6 P10635 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 2/20 0.32
ALDH1A1 P00352 2/20 0.32
HSD17B10 Q99714 1/20 0.32
RAB9A P51151 3/20 0.31
NPC1 O15118 2/20 0.31
CSNK1D P48730 1/20 0.31
MAPK11 Q15759 1/20 0.31
MAPK14 Q16539 1/20 0.31
GAA P10253 3/20 0.30
ADORA2A P29274 2/20 0.30
ADORA1 P30542 2/20 0.30
TSHR P16473 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13634342 0.85 NOS1 (0.38) SMN1; SMN2NOS1KMT2AMEN1SLC12A5
SCHEMBL232983 0.84 SMN1; SMN2 (0.40) SMN1; SMN2NOS1KMT2AMEN1SLC12A5
SCHEMBL22334912 0.84 SMN1; SMN2 (0.40) SMN1; SMN2NOS1KMT2AMEN1KDM4E
SCHEMBL3506347 0.83 MAPK1 (0.42) SMN1; SMN2NOS1KMT2AMEN1SLC12A5
SCHEMBL13634391 0.80 NOS1 (0.34) SMN1; SMN2NOS1KMT2AMEN1SLC12A5
SCHEMBL3556009 0.80 NOS1 (0.34) SMN1; SMN2NOS1KMT2ASLC12A5CYP2D6
SCHEMBL18674691 0.80 ALDH1A1 (0.35) SMN1; SMN2NOS1KMT2AMEN1SLC12A5
SCHEMBL25777808 0.79 MEN1 (0.40) KMT2AMEN1LMNACSNK1DMAPK11
SCHEMBL13425206 0.78 KDM4E (0.40) SMN1; SMN2KMT2AMEN1SLC12A5CYP2D6
SCHEMBL18674643 0.77 CRHR1 (0.36) SMN1; SMN2NOS1KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242535-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION BRISTOL MYERS SQUIBB CO (US) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242535-A1 IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION F2RL3, F2R, TMPRSS4 SMN1; SMN2 4341/4885NOS1 2314/4885KMT2A 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.